Plant ID: NPO21956
Plant Latin Name: Alyxia reinwardtii
Taxonomy Genus: Alyxia
Taxonomy Family: Apocynaceae
NCBI TaxonomyDB:
403097
Plant-of-the-World-Online:
n.a.
Thailand; Indonesia
GPR35; | |
NPSR1; | |
RECQL; TDP1; TERT; GLO1; HPGD; PGD; ALOX12; AKR1B1; HSD17B10; NOX4; APEX1; POLB; | |
ACHE; | |
BCL2; | |
TOP2A; | |
TEK; INSR; AXL; MET; FLT3; CDK1; EGFR; PIM1; NUAK1; SRC; KDR; IGF1R; AURKB; CSNK2A1; | |
KDM4E; | |
FUT7; | |
DNMT1; | |
ABCB1; | |
SLC22A6; | |
SMAD3; LMNA; HSPA1A; | |
L3MBTL1; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
ATP-binding cassette | ABCB1 | P-glycoprotein 1 | P08183 | CHEMBL4302 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
DNA methyltransferase | DNMT1 | DNA (cytosine-5)-methyltransferase 1 | P26358 | CHEMBL1993 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
Enzyme_unclassified | PGD | 6-phosphogluconate dehydrogenase | P52209 | CHEMBL3404 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Isomerase | TOP2A | DNA topoisomerase II alpha | P11388 | CHEMBL1806 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
Miscellaneous ion channel | BCL2 | Apoptosis regulator Bcl-2 | P10415 | CHEMBL4860 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Protein Kinase | TEK | Tyrosine-protein kinase TIE-2 | Q02763 | CHEMBL4128 |
Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
Unclassified | SMAD3 | Mothers against decapentaplegic homolog 3 | P84022 | CHEMBL1293258 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | HSPA1A | Heat shock 70 kDa protein 1 | P0DMV8 | CHEMBL5460 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0005488; binding | GO:0005524; ATP binding | 4.328E-10 | 2.547E-07 | ABCB1, AURKB, AXL, CDK1, CSNK2A1, EGFR, FLT3, HSPA1A, IGF1R, INSR, KDR, MET, NUAK1, PIM1, RECQL, SRC, TEK, TOP2A |
BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 3.483E-08 | 8.269E-06 | AXL, EGFR, INSR, MET, NOX4, SRC, TEK |
BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 5.448E-08 | 1.249E-05 | EGFR, IGF1R, INSR, KDR, SRC |
BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 2.066E-07 | 3.749E-05 | AKR1B1, APEX1, AXL, CDK1, CYP1B1 |
BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 6.265E-07 | 1.049E-04 | AXL, CDK1, CSNK2A1, EGFR, FLT3 |
MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 7.957E-07 | 1.313E-04 | EGFR, INSR, KDR |
MF | GO:0005488; binding | GO:0044877; macromolecular complex binding | 8.149E-07 | 1.334E-04 | ACHE, APEX1, CSNK2A1, EGFR, FLT3, IGF1R, INSR, KDR, L3MBTL1, PIM1, SMAD3, SRC |
BP | GO:0040011; locomotion | GO:0014911; positive regulation of smooth muscle cell migration | 1.081E-06 | 1.731E-04 | BCL2, NOX4, SRC, TERT |
BP | GO:0050896; response to stimulus | GO:0009611; response to wounding | 2.316E-06 | 3.384E-04 | ACHE, BCL2, CDK1, CYP1A1, EGFR, SMAD3 |
BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 4.616E-06 | 6.204E-04 | APEX1, POLB |
BP | GO:0051179; localization | GO:0051050; positive regulation of transport | 4.740E-06 | 6.331E-04 | ABCB1, ACHE, AXL, BCL2, CDK1, EGFR, INSR, NPSR1, SMAD3, SRC, TERT |
CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 5.325E-06 | 7.027E-04 | AKR1B1, APEX1, AURKB, BCL2, CDK1, CSNK2A1, DNMT1, HPGD, HSPA1A, L3MBTL1, LMNA, NUAK1, PIM1, POLB, RECQL, SMAD3, SRC, TERT, TOP2A |
BP | GO:0008152; metabolic process | GO:0045740; positive regulation of DNA replication | 6.075E-06 | 7.875E-04 | CDK1, EGFR, IGF1R, INSR |
BP | GO:0051179; localization | GO:1900182; positive regulation of protein localization to nucleus | 8.904E-06 | 1.108E-03 | CDK1, EGFR, SMAD3, SRC, TERT |
MF | GO:0005488; binding | GO:0019838; growth factor binding | 8.904E-06 | 1.108E-03 | EGFR, IGF1R, INSR, KDR, TEK |
BP | GO:0009987; cellular process | GO:0071363; cellular response to growth factor stimulus | 1.402E-05 | 1.632E-03 | EGFR, INSR, KDR, NOX4, SMAD3, SRC |
BP | Unclassified; | GO:0006461; protein complex assembly | 1.529E-05 | 1.743E-03 | ACHE, CDK1, HSD17B10, HSPA1A, IGF1R, INSR, SLC22A6, SMAD3, SRC, TEK, TERT |
BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 1.699E-05 | 1.897E-03 | AKR1B1, ALOX12, APEX1, CYP1A1, CYP1B1, HPGD, HSD17B10, KDM4E, NOX4, PGD |
BP | GO:0032502; developmental process | GO:0045766; positive regulation of angiogenesis | 2.024E-05 | 2.214E-03 | ALOX12, CYP1B1, KDR, TEK, TERT |
BP | GO:0065007; biological regulation | GO:0043406; positive regulation of MAP kinase activity | 2.138E-05 | 2.305E-03 | CDK1, EGFR, FLT3, INSR, NOX4, SRC |
MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 3.358E-05 | 3.250E-03 | AXL, IGF1R, INSR |
MF | GO:0005488; binding | GO:0042562; hormone binding | 3.441E-05 | 3.286E-03 | ACHE, EGFR, IGF1R, INSR |
BP | GO:0008152; metabolic process | GO:0043552; positive regulation of phosphatidylinositol 3-kinase activity | 3.725E-05 | 3.524E-03 | FLT3, SRC, TEK |
MF | Unclassified; | GO:0032403; protein complex binding | 4.251E-05 | 3.841E-03 | ACHE, APEX1, EGFR, FLT3, IGF1R, INSR, KDR, SMAD3, SRC |
BP | GO:0009987; cellular process | GO:2001240; negative regulation of extrinsic apoptotic signaling pathway in absence of ligand | 5.458E-05 | 4.704E-03 | BCL2, HSPA1A, TERT |
BP | GO:0009987; cellular process | GO:0051495; positive regulation of cytoskeleton organization | 6.256E-05 | 5.280E-03 | HSPA1A, MET, NOX4, SMAD3, TEK |
BP | GO:0009987; cellular process | GO:1900087; positive regulation of G1/S transition of mitotic cell cycle | 6.492E-05 | 5.409E-03 | APEX1, CYP1A1, TERT |
BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 6.566E-05 | 5.436E-03 | EGFR, KDR, NOX4, SRC, TEK |
BP | GO:0008152; metabolic process | GO:2001300; lipoxin metabolic process | 6.885E-05 | 5.604E-03 | ALOX12, HPGD |
BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 7.583E-05 | 6.060E-03 | BCL2, LMNA, SRC, TERT |
MF | GO:0005488; binding | GO:0031072; heat shock protein binding | 7.871E-05 | 6.195E-03 | CDK1, CSNK2A1, HSPA1A, KDR |
BP | GO:0065007; biological regulation | GO:0043393; regulation of protein binding | 7.926E-05 | 6.208E-03 | AURKB, BCL2, MET, SRC, TERT |
BP | GO:0050896; response to stimulus | GO:1901653; cellular response to peptide | 8.489E-05 | 6.555E-03 | AKR1B1, APEX1, IGF1R, INSR, SRC |
MF | GO:0005488; binding | GO:0003682; chromatin binding | 9.300E-05 | 7.032E-03 | APEX1, CDK1, DNMT1, EGFR, L3MBTL1, SMAD3, TOP2A |
BP | GO:0008152; metabolic process | GO:0045429; positive regulation of nitric oxide biosynthetic process | 9.620E-05 | 7.057E-03 | EGFR, INSR, SMAD3 |
BP | GO:0032501; multicellular organismal process | GO:0007435; salivary gland morphogenesis | 9.626E-05 | 7.057E-03 | EGFR, POLB |
MF | GO:0060089; molecular transducer activity | GO:0005021; vascular endothelial growth factor-activated receptor activity | 9.626E-05 | 7.057E-03 | FLT3, KDR |
BP | GO:0065007; biological regulation | GO:0048872; homeostasis of number of cells | 1.159E-04 | 8.062E-03 | AXL, BCL2, FLT3, POLB |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.273E-04 | 8.689E-03 | CYP1A1, CYP1B1, NOX4 |
MF | GO:0003824; catalytic activity | GO:0016616; oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | 1.279E-04 | 8.704E-03 | AKR1B1, HPGD, HSD17B10, PGD |
BP | GO:0009987; cellular process | GO:0006974; cellular response to DNA damage stimulus | 1.388E-04 | 9.328E-03 | APEX1, BCL2, CDK1, NUAK1, POLB, RECQL, TDP1, TOP2A |
BP | GO:0050896; response to stimulus | GO:0033993; response to lipid | 1.401E-04 | 9.388E-03 | AXL, BCL2, CSNK2A1, CYP1A1, EGFR, FLT3, HPGD, SRC |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 1.727E-10 | 2.210E-08 | SMAD3, CSNK2A1, SRC, INSR, MET, EGFR, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 2.597E-07 | 1.662E-05 | SRC, INSR, KDR, TEK, MET, EGFR, IGF1R |
09140 Cellular Processes | 09141 Transport and catabolism | hsa04144 | Endocytosis | 1.032E-06 | 4.403E-05 | SMAD3, SRC, KDR, MET, EGFR, HSPA1A, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 2.565E-06 | 6.565E-05 | DNMT1, ABCB1, PIM1, BCL2, CYP1B1, MET, EGFR |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 2.402E-06 | 6.565E-05 | INSR, BCL2, TEK, EGFR, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 6.361E-06 | 1.018E-04 | INSR, KDR, BCL2, TEK, MET, EGFR, IGF1R |
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 3.606E-06 | 6.983E-05 | INSR, CYP1A1, CYP1B1, IGF1R |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 3.819E-06 | 6.983E-05 | SRC, KDR, BCL2, MET, EGFR, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 7.460E-06 | 1.061E-04 | INSR, KDR, TEK, MET, EGFR, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 6.428E-05 | 8.228E-04 | SRC, KDR, MET, EGFR, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 1.688E-04 | 1.834E-03 | SMAD3, FLT3, BCL2, MET, EGFR, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 1.720E-04 | 1.834E-03 | SMAD3, INSR, EGFR, IGF1R |
09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 3.282E-04 | 3.231E-03 | INSR, HSPA1A, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 3.757E-04 | 3.349E-03 | FLT3, MET, EGFR |
09160 Human Diseases | 09167 Infectious diseases | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 3.925E-04 | 3.349E-03 | SRC, MET, EGFR |
09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 4.456E-04 | 3.565E-03 | MET, EGFR, IGF1R |
09160 Human Diseases | 09167 Infectious diseases | hsa05169 | Epstein-Barr virus infection | 8.373E-04 | 5.520E-03 | CSNK2A1, BCL2, CDK1, HSPA1A |
09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 5.438E-04 | 4.094E-03 | HPGD, FLT3, MET, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 8.625E-04 | 5.520E-03 | BCL2, EGFR, IGF1R |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.244E-03 | 7.237E-03 | SMAD3, PIM1, BCL2 |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 8.347E-04 | 5.520E-03 | SRC, CDK1, EGFR |
09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 1.174E-03 | 7.156E-03 | SRC, EGFR, HSPA1A |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR; |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; TERT; FLT3; DNMT1; |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
C00-D49: Neoplasms | CLL | NA | FLT3; |
C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; |
C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ABCB1; |
C00-D49: Neoplasms | Prostate cancer | C61 | TERT; FLT3; EGFR; BCL2; |
C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC; |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
C00-D49: Neoplasms | Advanced melanoma | C43 | BCL2; |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; EGFR; |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; EGFR; |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; DNMT1; EGFR; ABCB1; |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR; |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3; EGFR; |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | TEK; |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; |
H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | ABCB1; |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; ACHE; INSR; |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
NA: NA | Upper abdominal bloating | NA | ACHE; |
C00-D49: Neoplasms | Urethral cancer | NA | EGFR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | INSR; |
C00-D49: Neoplasms | Ovarian cancer | C56 | TERT; KDR; EGFR; ABCB1; |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR; |
C00-D49: Neoplasms | Tumors | C00-D48 | TERT; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR; |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; TERT; KDR; |
C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; BCL2; |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | DNMT1; |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; EGFR; BCL2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
C00-D49: Neoplasms | Lymphoma | C81-C86 | INSR; EGFR; BCL2; |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR; |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; TEK; DNMT1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; SRC; |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | INSR; |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; |
C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TERT; KDR; EGFR; AKR1B1; |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | TEK; SRC; |
C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR; |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; |
NA: NA | GIST | NA | FLT3; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; AKR1B1; |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | DNMT1; EGFR; SRC; |
C00-D49: Neoplasms | Glioma | C71 | KDR; EGFR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; EGFR; |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR; |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; TERT; SRC; BCL2; |
C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; TERT; KDR; FLT3; INSR; EGFR; BCL2; |
C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT; EGFR; SRC; |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | TERT; KDR; FLT3; EGFR; |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
C00-D49: Neoplasms | Melanoma | C43 | TERT; KDR; EGFR; |
C00-D49: Neoplasms | Soft tissue sarcoma | C00-D49 | DNMT1; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | TOP2A; MET; AURKB; IGF1R; KDR; FLT3; TEK; EGFR; SRC; ABCB1; |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
C00-D49: Neoplasms | Bladder cancer | C67 | EGFR; |
C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | INSR; AKR1B1; |
K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
G00-G99: Diseases of the nervous system G00-G99 | Amyotrophic lateral sclerosis | G12.2 | BCL2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; CSNK2A1; FLT3; ACHE; TEK; DNMT1; EGFR; SRC; ABCB1; BCL2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR; |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; BCL2; |